DNA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	71.16M
平均成交量	26.69M
市值	1.85B
EPS	$0 ( 2024-02-29 )
下一个收益日期	( $-0.0800 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.870
ATR14	$0.00300 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Dmytruk Mark E.	Sell	22 916	Restricted Stock Units
2024-04-01	Dmytruk Mark E.	Buy	1 634	Class A Common Stock
2024-04-01	Dmytruk Mark E.	Buy	22 916	Class A Common Stock
2024-04-01	Dmytruk Mark E.	Buy	18 125	Class A Common Stock
2024-04-01	Dmytruk Mark E.	Buy	65 448	Class A Common Stock

INSIDER POWER
-25.19
Last 100 transactions
Buy: 2 333 675 \| Sell: 4 285 014

音量相关性

長: 0.42 (neutral)

短: -0.66 (moderate negative)

Signal:(60.156) Neutral

Ginkgo Bioworks Holdings, 相关性

10 最正相关
ATTO	0.927
KT	0.92
DHX	0.918
ARMK	0.912
WF	0.911
PDS	0.911
WRBY	0.902
MYTE	0.902
AVYA	0.899
AMRC	0.899

10 最负相关
RXN	-0.884
MOG-B	-0.881
DSE	-0.872
COR	-0.872
MSP	-0.87
PSXP	-0.868
AMAM	-0.864
TNK	-0.855
CMO	-0.851
FPAC	-0.851

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Ginkgo Bioworks Holdings, 相关性 - 货币/商品

0.00
( neutral )

0.52
( weak )

Ginkgo Bioworks Holdings, 财务报表

Annual	2023
营收:	$251.46M
毛利润:	$142.64M (56.73 %)
EPS:	$-0.460

FY	2023
营收:	$251.46M
毛利润:	$142.64M (56.73 %)
EPS:	$-0.460

FY	2022
营收:	$477.71M
毛利润:	$273.49M (57.25 %)
EPS:	$-1.250

FY	2021
营收:	$313.84M
毛利润:	$204.16M (65.05 %)
EPS:	$-1.231

Financial Reports:

No articles found.

Ginkgo Bioworks Holdings,

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.